Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Consolidated Balance Sheets Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Prepaid Research And Development Asset, Current Prepaid research and development Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Total, property plant and equipment net Operating Lease, Right-of-Use Asset Right of use assets - operating leases Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable The carrying balance as of the balance sheet of accrued expenses and other current liabilities. Accrued Expenses and Other Current Liabilities. Accrued expenses and other current liabilities Accrued expenses and other current liabilities Contract with Customer, Liability, Current Non-refundable sublicense and transition services payments Non-refundable sublicense payments received Operating Lease, Liability, Current Operating lease liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Operating lease liabilities - noncurrent Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (note 10) Equity, Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both June 30, 2026 and December 31, 2025 Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balance at end of period Balance at beginning of period Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Consolidated Statements of Operations and Comprehensive Loss Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development Total research and development expenses General and Administrative Expense General and administrative Total general and administrative expenses Asset Impairment Charges Impairment of long-lived assets Gain (Loss) on Termination of Lease Net gain on lease terminations Net gain on lease termination Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) Other income (expense), net Net losses Net loss Net loss Earnings Per Share [Abstract] Per share information: Earnings Per Share, Basic Net loss per share of common stock, basic Earnings Per Share, Diluted Net loss per share of common stock, diluted Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding, diluted Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Unrealized gain (loss) on marketable securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common stock Additional Paid-in Capital [Member] Additional paid-in capital AOCI Attributable to Parent [Member] Accumulated other comprehensive income (loss) Retained Earnings [Member] Accumulated deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Stockholders' equity Shares, Outstanding Balance at end of period (in shares) Balance at beginning of period (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Exercise of stock options and vesting of restricted stock units (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of shares in connection with employee stock purchase plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of shares in connection with employee stock purchase plan (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation and amortization expense Share-Based Payment Arrangement, Noncash Expense Share-based compensation Amortization of Debt Discount (Premium) Amortization of premium and discount on marketable securities, net Other Noncash Expense Other non-cash items Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets, and other assets The amount of increase (decrease) in prepaid research and development. Increase (Decrease) In Prepaid Research and Development Prepaid research and development Increase (Decrease) in Contract with Customer, Liability Non-refundable sublicense and transition services payments received The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities. Increase (Decrease) in Right of Use Assets and Operating Lease Liabilities Right of use assets and operating lease liabilities Increase (Decrease) in Accounts Payable, Trade Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other current liabilities Net Cash Provided by (Used in) Operating Activities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows provided by (used in) investing activities: Proceeds from Sale and Maturity of Marketable Securities Sales or maturities of marketable securities Proceeds from Sale of Productive Assets Sales of property and equipment and other assets Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows provided by (used in) financing activities: Proceeds from Stock Plans Proceeds from the issuance of common stock under employee stock purchase plan Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of non-cash activities: Marketable Security, Unrealized Gain (Loss) Unrealized gain (loss) on marketable securities Nature of Operations Nature of Operations [Text Block] Nature of Operations No definition available. Risks, Liquidity, and Going Concern The entire disclosure of information pertaining to risk and liquidity. Risks And Liquidity [Text Block] Risks, Liquidity, and Going Concern Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value of Financial Instruments and Non-Financial Instruments Fair Value Disclosures [Text Block] Fair Value of Financial Instruments and Non-Financial Instruments Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Property and Equipment, Net Accrued Expenses and Other Current Liabilities The entire disclosure of information pertaining to accrued expenses and other current liabilities. Accrued Expenses And Other Current Liabilities Disclosure [Text Block] Accrued Expenses and Other Current Liabilities No definition available. Gemma License Agreement Collaborative Arrangement Disclosure [Text Block] Gemma License Agreement Severance Restructuring and Related Activities Disclosure [Text Block] Severance Leases Lessee, Operating Leases [Text Block] Leases Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stockholders' Equity and Share-Based Compensation Share-Based Payment Arrangement [Text Block] Stockholders' Equity and Share-Based Compensation Segment Reporting Segment Reporting Disclosure [Text Block] Segment Reporting Subsequent Events. Subsequent Events [Text Block] Subsequent Events Disclosure of accounting policy for basis of presentation. Basis Of Presentation [Policy Text Block] Basis of Presentation Disclosure of accounting policy for interim financial statements. Interim Financial Statements [Policy Text Block] Interim Consolidated Financial Statements Use of Estimates, Policy [Policy Text Block] Use of Estimates Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Marketable Securities, Policy [Policy Text Block] Marketable Securities Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment, Net Lessee, Leases [Policy Text Block] Leasing Research and Development Expense, Policy [Policy Text Block] Research and Development Disclosure of accounting policy for other income or other expense items. Other Income and Other Expense Policy [Policy Text Block] Other Income (Expense), Net Share-Based Payment Arrangement [Policy Text Block] Share-Based Compensation Revenue from Contract with Customer [Policy Text Block] License and Other Revenue Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of antidilutive securities excluded from computation of earnings per share Property, Plant and Equipment [Table Text Block] Schedule of property and equipment, net Tabular disclosure of information pertaining to accrued expenses and other current liabilities. Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block] Schedule of accrued liabilities and other current liabilities Lease, Cost [Table Text Block] Summary of operating leases Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of share-based compensation expense category Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of stock option activity plan Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted average assumptions applied to options Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of activity related to restricted stock unit Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Schedule of reconciliation of reported segment net loss to the statement of operations Amount of cash to be payable if the merger agreement is terminated. Merger Agreement, Termination Fee Payable Termination fee payable Schedule of information pertaining to risk and liquidity. Risks And Liquidity [Table] Sale of Stock [Axis] Sale of Stock [Domain] Represents the member information pertaining to at-the-market (ATM) facility. ATM Facility Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Risks And Liquidity [Line Items] Risks, Liquidity, and Going Concern Stock Issued During Period, Value, New Issues Sale of common stock, net of issuance costs The remaining capacity of value of shares available to be sold. Remaining Capacity of Value of Shares Available to Be Sold Remaining capacity available to be sold Antidilutive Security, Excluded EPS Calculation [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Computer Equipment [Member] Computer hardware Office Equipment [Member] Office equipment Represents the information pertaining to Laboratory equipment. Laboratory equipment Laboratory equipment Furniture and Fixtures [Member] Furniture and fixtures Represents information pertaining to laboratory equipment and certain other assets. Laboratory Equipment And Certain Other Assets [Member] Laboratory equipment and certain other assets Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Represents information pertaining to stock options (including shares subject to repurchase). Stock options (including shares subject to repurchase) Stock options Restricted Stock Units (RSUs) [Member] Unvested restricted stock units Employee Stock [Member] Employee stock purchase plan Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Summary of Significant Accounting Policies Stockholders' Equity Note, Stock Split, Conversion Ratio Stock split Stock Issued During Period, Shares, Reverse Stock Splits Stock issued during period, Reverse stock splits Debt Securities, Available-for-Sale, Current Marketable securities Property, Plant and Equipment, Useful Life Useful life Impairment of Long-Lived Assets to be Disposed of Impairment of property and equipment Impairment of long-lived assets Operating Lease, Impairment Loss Impairment expenses for right of use assets Investment Income, Net, Amortization of Discount and Premium Amortization of premium and discount Sublease Income Sublease income Sublease rental income Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Amount of antidilutive securities excluded from computation of earnings per share Fair Value, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 3 [Member] Level 3 Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Nonrecurring [Member] Nonrecurring basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Instruments and Non-Financial Instruments Property, Plant and Equipment [Table] Represents the information pertaining to Computer Hardware and Software. Computer hardware and software. Leaseholds and Leasehold Improvements [Member] Leasehold improvements Property, Plant and Equipment [Line Items] Property and Equipment, Net Property, Plant and Equipment, Gross Total property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation and amortization Long-Lived Asset, Held-for-Sale, Type [Axis] Long-Lived Assets Held-for-Sale, Name [Domain] Represents the operating lease agreement for office space. Operating Leases For Office Space Operating leases for office space Represents the operating lease agreement for laboratory space. Operating Leases For Laboratory Space Operating leases for laboratory space Amount of expense incurred during the period for early lease termination. Early Lease Termination Fee Payment for early lease termination Amount of gain (loss) on write-off of assets and liabilities for operating leases. Gain (Loss) On Write Off Of Operating Leases Gain (loss) on write-off of operating leases Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of property and equipment Loss on disposal of property and equipment Accrued Professional Fees, Current Professional fees Employee-related Liabilities, Current Compensation and related benefits The carrying balance as of the balance sheet of accrued research and development expense. Accrued Research And Development Expense Research and development Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Divestiture Fees, Current Divestiture fee due to Catalent Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents information pertaining to the arrangement with Gemma Biotherapeutics Inc. Arrangement With Gemma Biotherapeutics Inc [Member] Gemma License Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Commitments and Contingencies Amount of upfront license fee that is receivable under the license arrangement. Upfront License Fee Receivable Upfront license fee receivable The cash inflow from non-refundable sublicense payments received. Proceeds From Non-Refundable Sublicense Payments Payment received Amount of license fee due and receivable in long-term as of the balance sheet date under the license agreement. Long-Term License Fee Due And Receivable Long-term license fee due and receivables Contingent proceeds upon completing certain business milestones. Contingent Proceeds From Upon Completion of certain business milestones Contingent proceeds upon completing certain business milestones The maximum additional amount in development and commercial milestone payments receivable. Maximum Additional Amount in Development And Commercial Milestone Payments Receivable Maximum additional amount in development and commercial milestone payments receivable The cash inflow from non-refundable transition service payments received by the company. Proceeds From Non Refundable Transition Services Payments Amount of transition services payments The amount of decrease in payable due to amounts received under transition service payments. Payable, Decrease from Amounts Received Transition Services Payments Transition service payments Restructuring Cost [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] General and Administrative Expense [Member] General and administrative expense General and administrative Research and Development Expense [Member] Research and development Restructuring Type [Axis] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance Workforce reduction Restructuring Cost and Reserve [Line Items] Severance Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Workforce reduction Severance Costs Severance and termination-related expenses Restructuring Reserve Unpaid severance Lessee, Lease, Description [Table] Represents information pertaining to Sublease Agreement A. Sublease Agreement A [Member] Sublease Agreement A Represents information pertaining to Sublease Agreement B. Sublease Agreement B [Member] Sublease Agreement B Represents information pertaining to Sublease Agreement C. Sublease Agreement C [Member] Sublease Agreement C Lessee, Lease, Description [Line Items] Area subleased. Area Subleased Represents are of land sub leased of the total area under lease. Area of Land subleased, Percentage Subleased area of land Area of Land Area leased Lessee, Operating Lease, Existence of Option to Extend [true false] Option to extend lease Represents the number of extensions available under the new lease arrangement. New Lease Agreement, Operating Lease, Number Of Extensions Number of extension terms Lessee, Operating Lease, Remaining Lease Term Renewal term of lease Represents the percentage of annual increase in sublease rent. Percentage of Annual Increase in Sublease Rent Annual increase in sublease rent (as a percent) Represents the renewal term under new lease agreement. New Lease Agreement, Operating Lease, Renewal Term Extended term of new lease agreement Amount of increase (decrease) in right of use assets. Increase (Decrease) In Right Of Use Assets ROU assets decrease Increase (Decrease) in Operating Lease Liability Operating leases decreased Right of Use period decrease due to lease termination. Right of Use Period Decrease due to Lease Termination Lease Liability for Operating Lease, Period Decrease due to Lease Termination. Lease Liability For Operating Lease, Period Decrease due to Lease Termination Operating Lease, Cost Operating lease expense Variable Lease, Cost Variable lease expense Lease, Cost Lease expense Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term (years) Operating Lease, Payments, Use Operating lease payments Represents the information pertaining to amended and restated research, collaboration and license agreement with Penn. Amended and restated agreement with Penn Amended and restated agreement The amount of payable per product candidate for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement. Collaboration Agreement, Amount Payable Per Product Candidate for Rare Monogenic Disorders, Upon Achievement Of Specific Development Milestone Amount payable per product candidate for rare, monogenic disorders The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement. Collaboration Agreement Amount Payable Per Product Candidate Upon Achievement Of Specific Development Milestone Amount payable per product candidate upon achievement of specific development milestone The amount of payable on sales milestone payment on collaboration and license agreement. Collaboration Agreement Sales Milestone Payments Payable Sales milestone payments Amount of aggregate non-refundable fees payable per product indication. Non - Refundable Aggregate Fees Payable Per Product Indication Non - Refundable aggregate fees payable Amount of upfront fees payable per product indication. Non - Refundable Upfront Fees Payable Per Product Indication Non - Refundable upfront fees payable Amount of upfront fees payable per product indication upon developmental milestone. Non - Refundable Fees Payable Per Product Indication Upon Developmental Milestone Non - Refundable fees payable Amount of cash outflow for payment of divestiture fees. Divestiture Fees Paid Paid catalent fee Loss Contingency Accrual Amount of loss contingency The number of stock issued during period for settlement of litigation. Stock Issued During Period, Settlement of Litigation Common stock Number of shares agreed to be issued by defendant and subject to reverse stock split. Loss Contingency, Shares Agreed by Defendant Loss contingency, shares agreed by defendant Represents the percentage of target annual bonus amounts. Percentage of Target Annual Bonus Amounts Target annual bonus Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to Equity Incentive Plan. Equity Incentive Plan [Member] Equity Incentive Plan Represents information pertaining to 2021 Equity Inducement plan. Equity Inducement Plan 2021 Equity inducement plan 2021 Represents information pertaining to Employee Stock Purchase Plan. Employee Stock Purchase Plan Employee stock purchase plan Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Represents the number of equity incentive plans. Number Of Equity Incentive Plans Number of equity incentive plans Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares authorized Common Stock, Capital Shares Reserved for Future Issuance Shares available for future issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares available for future grant Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement. Share Based Payment Arrangement, Period Till Which Automatic Increase In Rights Granted Period till which there is automatic increase in rights granted under the Plan Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement Share Based Payment Arrangement, Percentage Of Outstanding Common Shares As Automatic Increase Percent of the total number of shares of the Company's common stock outstanding Additional number of common shares reserved for future issuance. Common Stock, Additional Capital Shares Reserved for Future Issuance Additional number of common shares reserved for future issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period Duration from date of grant (issuance of an option) to when option auto expires. Share-based Compensation Arrangement By Share-based Payment Award Term Term of award Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan. Employee Stock Purchase Plan, Period Till Which Automatic Increase In Rights Granted Period till which there is automatic increase in rights granted under ESPP Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan. Employee Stock Purchase Plan Issuance, Percentage Of Common Stock Outstanding Percentage of common stock outstanding The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP. Employee Stock Purchase Plan, Stock Purchase Price Percentage Percentage of stock purchase price Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan. Employee Stock Purchase Plan, Maximum Employee Contribution Percentage Percentage of maximum employee contribution The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding. Employee Stock Purchase Plan, Maximum Amount Of Common Stock That Can Be Purchased Maximum amount of common stock that can be purchased Share-Based Payment Arrangement, Expense Share-based compensation expense Threshold number of shares that can be purchased in any single offering period. Employee Stock Purchase Plan, Threshold Number Of Shares That Can Be Purchased Number of shares that can be purchased Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, Ending of period Outstanding, Beginning of period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Vested and exercisable at June 30, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested or expected to vest at June 30, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, Ending of period Outstanding, Beginning of period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vested and exercisable at June 30, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested or expected to vest at June 30, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining contractual term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested and exercisable at June 30, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested or expected to vest at June 30, 2026 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value of options granted Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrecognized compensation expense related to unvested stock option awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average period for recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Unvested balance, Ending Unvested balance, Beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unvested balance, Weighted average grant date fair value, Ending Unvested balance, Weighted average grant date fair value, Beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested, Weighted average grant date fair value Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Total unrecognized expense Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Segments [Axis] Segments [Domain] Represents information pertaining to developing and advancing of genetic medicines. Genetic Medicines Segment [Member] Genetic Medicines Segment Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting Number of Reportable Segments Number of reportable segments Research and Development Expense [Abstract] Research and development Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit directly attributable to research and development phase of the medicines. Research And Development, Labor And Related Expenses Wages, benefits, and other payroll Amount of expenses in the period for usage of third party costs attributable specifically to research and development division. Research and Development, Third Party Costs Third-party costs Amount of expenses in the period for usage of share based compensation attributable specifically to research and development division. Research and Development, Share Based Compensation Share-based compensation Amount of expenses in the period for usage of depreciation and amortization attributable specifically to research and development division. Research and Development, Depreciation and Amortization Depreciation and amortization General and Administrative Expense [Abstract] General and administrative Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit, excluding wages and other benefits incurred for employees in research and development phase of the medicines. General And Administrative, Labor And Related Expenses Wages, benefits, and other payroll Amount of expenses in the period for usage of third party costs attributable to managing and administering the affairs of an entity. General and Administrative, Third Party Costs Third-party costs Amount of expenses in the period for usage of share based compensation attributable to managing and administering the affairs of an entity. General and Administrative, Share Based Compensation Share-based compensation Amount of expenses in the period for usage of depreciation and amortization attributable to managing and administering the affairs of an entity General and Administrative, Depreciation and Amortization Depreciation and amortization Represents information pertaining to rule 10b5-1 arrangement Modified. Rule 10b5-1 Arrangement Modified Represents information pertaining to non-rule 10b5-1 arrangement Modified. Non-Rule 10b5-1 Arrangement Modified